Identification of acetylation-dependent regulatory mechanisms that govern the oncogenic functions of Skp2 by Wang, Zhiwei et al.
 
Identification of acetylation-dependent regulatory mechanisms that
govern the oncogenic functions of Skp2
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Wang, Zhiwei, Hiroyuki Inuzuka, Jiateng Zhong, Pengda Liu,
Fazlul H. Sarkar, Yi Sun, and Wenyi Wei. 2012. “Identification of
acetylation-dependent regulatory mechanisms that govern the
oncogenic functions of Skp2.” Oncotarget 3 (11): 1294-1300.
Accessed February 19, 2015 2:02:31 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11717610
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAOncotarget 2012; 3: 1294-1300 1294 www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/  Oncotarget, November, Vol.3, No 11
Identification of acetylation-dependent regulatory mechanisms 
that govern the oncogenic functions of Skp2 
Zhiwei Wang1, Hiroyuki Inuzuka1, Jiateng Zhong1,2, Pengda Liu1, Fazlul H. Sarkar3, 
Yi Sun4, and Wenyi Wei1
1 Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 
2 Department of Pathophysiology, Norman Bethune College of Medicine, Jilin University, Changchun, Jilin , P. R. China
3 Department of Pathology and Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 
4 Division of Radiation and Cancer Biology, Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 
Correspondence to: Wenyi Wei, email: wwei2@bidmc.harvard.edu 
Keywords: acetylation, cancer, deacetylation, SIRT3, oncoprotein, ubiquitination, phosphorylation, F-box protein, Skp2, therapy
Received:  November 06, 2012,  Accepted: November 14, 2012,  Published: November 16, 2012
Copyright: © Wang et al.  This is an open-access article distributed under the terms of the Creative Commons Attribution License, which 
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT:
The Skp2 (S-phase kinase associated protein 2) oncoprotein is often highly 
expressed in various types of human cancers. However, the mechanistic basis of 
its oncogenic function, as well as the upstream regulatory pathway(s) that control 
Skp2  activities  remains  not  fully  understood.  Recently,  we  reported  that  p300 
acetylates Skp2 at two conserved lysine residues K68 and K71 within its NLS (Nuclear 
localization signal). This modification leads to increased Skp2 stability and cytoplasmic 
translocation, thus contributing to elevated Skp2 oncogenic potential. Moreover, we 
found that the SIRT3 tumor suppressor serves as the physiological deacetylase that 
antagonizes p300-mediated Skp2 acetylation. Furthermore, we showed that Skp2 
governs E-cadherin ubiquitination and degradation in the cytosol. Consistent with 
this, we observed an inverse correlation between Skp2 and E-cadherin expression 
in clinical breast tumor samples. Therefore, our work elucidates a novel acetylation-
dependent regulatory mechanism for Skp2 oncogenic functions.  
INTRODUCTION
The Skp2 F-box protein is a substrate recognizing 
component of the SCF (Skp1-Cullin 1-F-box) type of E3 
ubiquitin-ligase complex [1]. It is known that the SCF 
complex consists of four crucial components including 
the invariable component Skp1, Rbx1 and Cullin1, and 
the interchangeable substrate-recruiting module, the 
F-box protein [1]. Among 70 putative F-box proteins, 
Skp2 is one of the best characterized F-box protein and 
has been shown to be involved in governing many cellular 
processes such as cell cycle regulation, cell proliferation, 
apoptosis, differentiation, and survival, in part through 
promoting the degradation of its substrate proteins [2, 
3]. For example, Skp2 plays an important role in driving 
the cell cycle through the G1/S transition by promoting 
the destruction of the p27 tumor suppressor protein, an 
inhibitor of the CDK (Cyclin-dependent kinase) family 
of kinases [4, 5]. In addition to p27 [6], recent studies 
have identified numerous downstream Skp2 substrates 
including p21, p57, p130, c-Myc, FOXO1 (Forkhead box 
protein O1) [7-10], and Tob1[11] (Figure 1). 
The fact that many Skp2 substrates are negative cell 
cycle regulators is consistent with the notion that Skp2 
mainly functions as a proto-oncogene. Indeed, Skp2 has 
been found to be frequently overexpressed in a variety 
of human cancers including lymphomas [12], prostate 
cancer [13], melanoma [14], nasopharyngeal carcinoma 
[15], pancreatic cancer [16], and breast carcinomas [17, 
18]. More importantly, in support of an oncogenic role for 
Skp2 in tumor progression, Skp2-/- mice has been found to 
be resistant to tumor development induced by loss of either 
the p53 or the PTEN tumor suppressor [19]. Although 
multiple signaling pathways such as phosphatidylinositol 
3-kinase (PI3K)/Akt [20], AR (Androgen receptor) [21], 
PTEN (Phosphatase and tensin homolog) [13] and STAT1 
(Signal transducers and activators of transcription) [22] 
have been reported to cross-talk with the Skp2 sinaling 
pathway and subsequently lead to tumorigenesis, the 
underlying mechanism(s) by which Skp2 is regulated Oncotarget 2012; 3: 1294-1300 1295 www.impactjournals.com/oncotarget
in vivo remains largely elusive. Here, we will discuss 
the recent advances in our understanding of how 
Skp2 oncogenic role is governed in vivo by the novel 
acetylation-dependent mechanism, which is antagonized 
by the SIRT3 deacetylase.
Skp2 is acetylated by p300
Multiple studies have shown that phosphorylation 
of Skp2 by Akt at Ser72 protects Skp2 from APC 
(Anaphase-promoting complex)/Cdh1-mediated 
proteolysis [23, 24]. However, Ser72 is only present in 
human and large mammals, but not conserved in mice, 
suggesting that Akt-mediated Skp2 phosphorylation 
might be a regulatory mechanism acquired late during 
the evolution. This implies that additional mechanisms 
might exist to regulate Skp2 activity. It is noteworthy 
that besides protein phosphorylation, protein acetylation 
has been recently demonstrated to emerge as another 
important  type  of  post-translational  modification  that 
modulates many pathways involved in oncogenesis [25, 
26]. More interestingly, while PI3K/Akt phosphorylates 
and activates acetyl-transferase p300 [27], Skp2 binds, 
but inhibits p300 to block p53-induced apoptosis [28]. 
Consistently, we found that interaction between p300 and 
Skp2 under both ectopic overexpression and endogenous 
co-immunoprecipitation conditions can readily be detected 
[29]. Furthermore, acetylation of Skp2 is detected using 
a specific acetyl-lysine antibody after ectopic expression 
of p300 [29]. Notably, we found that p300 acetylates 
the Skp2 oncoprotein at both K68 and K71 within its 
nuclear localization signal (NLS) region, just adjacent to 
the identified Ser72 Akt site [29]. Moreover, we found 
that p300-mediated Skp2 acetylation promotes Skp2 
dimerization, suggesting that dimerization might affect 
the Skp2 substrate spectrum. To our knowledge, this is 
the first example demonstrating acetylation of an F-box 
protein, thereby suggesting the possibility of acetylation-
dependent regulation of F-box protein(s) other than 
Skp2. In keeping with this note, recent large-scale mass 
spectrometry  analyses  have  shown  that  a  significant 
number of cellular proteins are acetylated [30, 31], 
although it is largely unclear how acetylation functions as 
a signaling mechanism to modulate downstream signaling 
and cellular physiology. Therefore, further studies are 
warranted to explore how analogous to phosphorylation-
dependent regulation mechanism, acetylation could be 
utilized to govern the physiological functions of various 
F-box proteins.
Interestingly, Akt activates p300 acetyl-transferase 
activity  to  influence  the  Skp2  acetylation.  However, 
p300 exerts its function independent of the Akt-Ser72-
Skp2 pathway [29]. Therefore it is critical to further 
understand the possible redundancy or cross-talks 
between these two upstream regulatory pathways, 
Akt-mediated phosphorylation of Ser72 versus p300-
mediated acetylation of Skp2, in terms of promoting 
Skp2 oncogenic signaling. It is possible that p300 and Akt 
are activated in response to distinct upstream signals to 
modulate Skp2 activity in specific settings. Alternatively, 
they share redundant functions with the p300 pathway 
being the ancestral mechanism of regulation, and Akt-
mediated regulation acquired later in evolution. Obviously 
additional studies will be required to fully dissect the 
potential intercommunication between the p300 and Akt 
signal transduction pathways that modulate Skp2 activity.
Skp2 is deacetylated by the SIRT3 tumor 
suppressor
The Sirtuin (SIRT) family of deacetylases have 
recently gained tremendous amount of attention due to 
their critical roles in many cellular functions [9]. The 
Sirtuins play important roles in a variety of cellular 
processes including aging, cellular metabolism and 
tumorigenesis [32]. Interestingly, Sirtuins are located in 
different cellular compartments, which may dictate the 
specific cellular function of each Sirtuin protein through 
promoting the deacetylation of various target proteins such 
as FOXO3a [33, 34], PPARγ (Peroxisome proliferators-
activated receptor gamma) [35] and p53 [36]. For example, 
SIRT1, the best-characterized member of the mammalian 
Sirtuins, is located predominately in the nucleus [37, 38], 
whereas SIRT2 is found in the cytosol [39, 40]. SIRT3, 
SIRT4 and SIRT5, on the other hand, are localized mainly 
in the mitochondria [41, 42], [43]. 
Recent studies have also shown that SIRT3 has 
seemingly dichotomous role as either tumor promoter or 
tumor suppressor in cancer biology. For example, SIRT3 
expression was found significantly higher in oral cancer 
cell lines and human oral cancer samples than in normal 
control [10]. In contrast, SIRT3 was reported to suppress 
tumor growth via induction of growth arrest and apoptosis 
in colorectal carcinoma, osteosarcoma cells, ovarian 
cancer, prostate cancer, suggesting that SIRT3 is tumor 
suppressor in these cancers [9]. Several published papers 
demonstrated a tumor suppressor role for SIRT3 via the 
ability of SIRT3 to negatively regulate ROS (reactive 
oxygen species) and HIF1-α (hypoxia inducible factor-1 
α) [44, 45]. However, the exact mechanisms how SIRT3 
is involved in cancer are largely unclear. 
Our recent study showed that SIRT3 interacts with 
Skp2 and subsequently deacetylates Skp2 to suppress 
tumorigenesis [29]. Specifically, only SIRT3 and SIRT4 
specifically interact with Skp2 among the various Sirtuin 
family members [29]. As SIRT3 is a tumor suppressor 
protein [45, 46], we further examined a potential role for 
SIRT3 in regulation of Skp2 acetylation. We detected a 
specific interaction between ectopically expressed as well 
as endogenous Skp2 and SIRT3. Moreover, depletion of 
SIRT3 caused an increase in endogenous Skp2 acetylation Oncotarget 2012; 3: 1294-1300 1296 www.impactjournals.com/oncotarget
[29]. Additionally, depletion of SIRT3 also leads to a 
moderate increase in Skp2 abundance, which correlates 
with decreased expression of the Skp2 substrates p27 and 
p21. More importantly, the inverse correlation between 
Skp2 and SIRT3 immunohistochemical staining was 
observed in breast cancer tissues [29]. As SIRT3 has been 
implicated to possess tumor suppressor function [45, 46], 
this result suggests that loss of SIRT3 may lead to elevated 
Skp2 expression in breast cancers. In support of a tumor 
suppressor function for SIRT3, it has also been reported 
previously that SIRT3-/- cells displayed elevated ability to 
form tumors in a xenograft model and loss of SIRT3 has 
been identified as a frequent event in breast cancer cases 
[45, 46]. Using the xenograft model, we further showed 
that depletion of Skp2 retarded the in vivo tumorigenesis 
of SIRT3-/- cells [29]. Altogether, our results suggest that in 
our experimental settings, SIRT3 inhibited tumor growth 
mainly through deacetylation of Skp2 oncoprotein. Future 
study is directed to mechanistically understand how 
and whether SIRT3 exerts its tumor suppressor function 
by inactivating the Skp2 oncogenic pathway solely in a 
deacetylase-dependent manner.
Skp2 acetylation governs its oncogenic function
The regulation of proteins by acetylation/
deacetylation  is  considered  as  a  significant  post-
translational regulatory mechanism to modify the specific 
enzyme’s activity [47]. Hence, we intended to examine 
whether acetylation of Skp2 controls its oncogenic 
functions. Notably, we found that acetylation of Skp2 
positively regulates its oncogenic activity partly through 
modulating its stability [29]. Moreover, acetylation 
of Skp2 exerts its function through promoting the 
destruction of its downstream targets such as p21 and 
FOXO1. To further support the role of Skp2 acetylation 
in tumorigenesis, depletion of endogenous SIRT3, which 
leads to increased acetylation of Skp2, promotes cell 
growth [29].  
A canonical NLS was identified at the Skp2 amino 
terminus, and its function is highlighted by the fact that 
over-expression of an active Akt allele relocalizes a pool 
of Skp2 to the cytoplasm [23, 24]. Acetylation of lysines 
within an NLS has been reported to influence cellular 
localization [48-51]. Therefore, we detected whether 
acetylation  of  Skp2  NLS  influences  its  localization. 
Consistent with the fact that Skp2 acetylation sites are 
found within its NLS, p300 promotes Skp2 cytoplasmic 
localization [29]. Interestingly, p300-induced Skp2 
cellular localization is independent of Akt-mediated Skp2 
phosphorylation [29]. In support of this notion, Skp2 
cytoplasmic localization has been observed in many 
clinical tumor samples and is correlated with aggressive 
malignancy and poor diagnosis [17, 52-54]. Taken 
together, our results demonstrate that p300-mediated 
acetylation of Skp2 affects its stability and cytoplasmic 
localization, which in turn can influence its oncogenic 
activity. These results suggest that acetylation-mediated 
Figure 1: Illustrated pathway of Skp2-mediated degradation of its substrates. The SCF (Skp1-Cullin 1-F-box) complex 
consists of four components: Skp1, Rbx1, Cullin1, and the F-box protein. While Skp2 recognizes its downstream substrates, cullin1-Rbx1 
complex catalyzes the ubiquitin transfers from E2 to the substrates for targeted degradation by 26S-proteasome. The multiple substrates 
including p21, p27, p57, p130, Tob1, FOXO1, E-cadherin, and c-Myc have been identified.  Oncotarget 2012; 3: 1294-1300 1297 www.impactjournals.com/oncotarget
post-translational modifications might also control the 
function of other F-box proteins.
Skp2 regulates cell migration through promoting 
E-cadherin destruction
It has been well accepted that enhanced cell 
migration is a critical phenotype required for cancer 
progression that leads to invasion and ultimately metastatic 
dissemination of tumor cells. In addition to controlling cell 
cycle progression, Skp2 has also been implicated in the 
regulation of cell migration. For example, a study showed 
that ectopic expression of Skp2 fused with an extra copy 
of an NES rescues the deficiency of cell motility in Skp2-/- 
MEFs, in the absence of p27 degradation [23], indicating 
that cytoplasmic Skp2 may have a distinct function 
related to cell migration, independent of its major role 
in cell cycle regulation. Indeed, a correlation between 
elevated Skp2 protein expression and tumor metastasis 
has been noted in multiple tumors, including melanoma, 
lymphoma and breast carcinoma [55-57]. Furthermore, 
several studies have demonstrated that cytosolic Skp2 can 
positively regulate cell migration, although the molecular 
mechanisms are largely unknown [23]. As we have shown 
that acetylation promotes cytosolic localization, it became 
increasingly necessary to explore whether acetylation 
could influence Skp2-governed cellular migration.
To this end, E-cadherin is considered as a major 
player in EMT (epithelial to mesenchymal transition) 
[58]. It is accepted that after EMT, cells lose epithelial 
features including down-regulation of E-cadherin and 
gain mesenchymal characteristics such as upregulation 
of  N-cadherin,  fibronectin,  and  vimentin,  leading  to 
enhanced cell migration, invasion and metastasis [44, 
59, 60]. Consistent with this notion, loss of E-cadherin is 
frequently observed in high-grade breast tumor samples 
[61-63]. However, it remains unclear whether enhanced 
proteolysis of E-cadherin also contributes to the reduced 
E-cadherin abundance in high-grade breast tumors. On the 
other hand, Skp2 is found to be frequently overexpressed 
in various types of cancers including breast cancer [1]. We 
therefore propose that aberrant Skp2 signaling may lead 
to elevated E-cadherin destruction that in turn profoundly 
affects cell migration and potentially EMT. In keeping with 
this hypothesis, our study indicates that Skp2 promotes 
cellular migration partly through promotion of E-cadherin 
destruction [29]. Furthermore, we observed an inverse 
correlation between Skp2 and E-cadherin expression in an 
array of breast cancer clinical samples [29]. Interestingly, 
Figure 2: Proposed model for how Skp2 oncogenic role is regulated by p300 and SIRT3. A. Skp2 is acetylated by the 
p300 acetyl-transferase at both K68 and K71, leading to increased Skp2 stability and its oncogenic functions partly through promoting 
its cytoplasmic localization. Moreover, Skp2 promotes tumor cell migration via governing E-cadherin degradation. Furthermore, SIRT3 
interacts with and deacetylates Skp2 to antagonize the acetylation by p300. B. Schematic illustration of how p300-dependent acetylation of 
Skp2, a process that can be antagonized by the SIRT3 deacetylase, leads to elevated Skp2 oncogenic functions in part by stabilizing Skp2 
as well as promoting Skp2 cytoplasmic localization.Oncotarget 2012; 3: 1294-1300 1298 www.impactjournals.com/oncotarget
we found that although ectopic expression of Skp2 in 
LNCaP cells leads to decreased expression of E-cadherin 
and α-E-catenin, other molecular markers for EMT were 
not significantly altered [29]. These results argue that 
cytoplasmic Skp2 preferentially promotes E-cadherin 
destruction to regulate cellular migration, but has nominal 
effects on other cell adhesion proteins, implying that 
additional oncogenic signaling, which is not currently 
fully underscored, is required for promoting full EMT. 
Therefore, additional studies are required to pinpoint these 
genetic alterations that might synergize with elevated Skp2 
oncogenic signaling in facilitating cellular transformation 
and metastasis.
CONCLUSION
In conclusion, Skp2 plays an oncogenic role in the 
development and progression of human cancers through 
degradation of its downstream target proteins that control 
a variety of cellular processes such as cell proliferation, 
apoptosis, migration, invasion and metastasis. More 
importantly, we recently identified that Skp2 is acetylated 
by p300, resulting in its cytoplasmic localization and 
enhanced stability. We further  demonstrate that the SIRT3 
tumor suppressor interacts with and deacetylates Skp2 
(Figure 2), suggesting that targeting Skp2 or the p300/
SIRT3 axis could be a novel approach for the treatment 
of human cancers, especially those with up-regulation of 
Skp2. However, we recognize that although these studies 
provide the molecular basis for targeting Skp2 as novel 
anti-cancer therapeutic options, further in-depth studies 
are required to provide further insights to guide the design 
of effective therapeutics targeting Skp2 acetylation events 
to combat human cancers.
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